Results for carboplatin translation from English to Slovenian

carboplatin
karboplatin

carboplatin/
karboplatin in

carboplatin/ paclitaxel
karboplatin in paklitaksel

+ carboplatin (n=521)
+ karboplatin (n=521)

carboplatin arm (n=174)
veja s karboplatinom (n=174)

erlotinib and carboplatin/paclitaxel
erlotinib in karboplatin/paklitaksel

gemcitabine plus carboplatin arm (n=175)
veja z gemcitabinom in karboplatinom (n=175)

dose of carboplatin (auc mg•min/ml)1
odmerek karboplatina (auc mg•min/ml)1

values presented are for iressa versus carboplatin/paclitaxel.
prikazane so vrednosti za zdravilo iressa v primerjavi s karboplatinom/paklitakselom.

in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin.
v kombinaciji z adjuvantno kemoterapijo z docetakselom in karboplatinom;

together with trastuzumab and carboplatin (another anticancer medicine).
skupaj s trastuzumabom in karboplatinom (drugim zdravilom proti raku).

there were no clinically relevant pharmacokinetic interactions between abraxane and carboplatin.
med zdravilom abraxane in karboplatinom ni bilo klinično pomembnih farmakokinetičnih interakcij.

no patients treated with abraxane and carboplatin experienced grade 4 peripheral neuropathy.
noben bolnik, zdravljen z zdravilom abraxane in karboplatinom, ni imel periferne nevropatije 4. stopnje.

there were no significant effects of carboplatin or paclitaxel on the pharmacokinetics of erlotinib.
pomembnih učinkov karboplatina ali paklitaksela na farmakokinetiko erlotiniba ni bilo.

non-small cell lung cancer (abraxane administered in combination with carboplatin)
nedrobnocelični pljučni rak (zdravilo abraxane uporabljeno v kombinaciji s karboplatinom)

limited data from a single uncontrolled study were suggestive of an interaction between docetaxel and carboplatin.
omejeni podatki iz ene same nekontrolirane študije so nakazovali interakcijo med docetakselom in karboplatinom.

table 4 quality of life outcomes for gefitinib versus carboplatin/paclitaxel from the ipass study
preglednica 4 izidi kakovosti življenja z gefitinibom v primerjavi s karboplatinom/paklitakselom v študiji ipass

a pharmacokinetic study was conducted with abraxane and carboplatin in non-small cell lung cancer patients.
pri bolnikih z nedrobnoceličnim pljučnim rakom so opravili farmakokinetično študijo z zdravilom abraxane in karboplatinom.

concomitant administration of lenvatinib, carboplatin, and paclitaxel has no significant impact on the pharmacokinetics of any of these 3 substances.
sočasna uporaba lenvatiniba, karboplatina in paklitaksela ni pomembno vplivala na farmakokinetiko katere koli od teh treh snovi.

in clinical practice, there may be other co-factors leading to an increased exposure to carboplatin like renal impairment.
v klinični praksi lahko obstajajo drugi dejavniki, ki vodijo k večji izpostavljenosti karboplatinu, kot je npr. ledvična okvara.